Aptevo Offloads Ruxience Biosimilar Rights In $67.5m Deal

Aptevo currently receives a 2.5% royalty from Pfizer

 
• By Dean Rudge
  
Pedestrians wearing a protective mask walks past Pfizer Inc. headquarters on July 22, 2020 in New York City.
Pfizer launched the Ruxience biosimilar in the US, EU and Japan in 2020 • Source: Shutterstock (Jeenah Moon/Getty Images)

More from Biosimilars

More from Products